Drug Trial Radar · NCT07334886
A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Sep 17, 2025
Primary completion
Nov 11, 2025
Study completion Nov 11, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.
Conditions
- Healthy
Interventions
[14C]UlonivirineDrug
Oral Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Percentage of Total Radioactivity Recovered (FE) from Urine and FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- FE from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- FE from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Cumulative Amount of Radioactivity Recovered from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Percent of Total Radioactive Dose Recovered from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Cumulative Amount of Radioactivity Recovered from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Percent of Total Radioactive Dose Recovered from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Concentration (AUC0-last)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
- Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
- Plasma Ulonivirine: Maximum Observed Concentration (Cmax)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
- Plasma Ulonivirine: Concentration at 168 Hours Postdose (C168)Time frame: At approximately 1 week postdose
- Plasma Ulonivirine: Terminal Half-life (t1/2)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
- Plasma Ulonivirine: Time of Maximum Observed Concentration (Tmax)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
- Ratio of Ulonivirine to Total Plasma Radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)Time frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Total Radioactivity: AUC0-lastTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Total Radioactivity: AUC0-infTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Total Radioactivity: CmaxTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Total Radioactivity: C168Time frame: At approximately 1 week postdose
- Plasma Total Radioactivity: t1/2Time frame: At designated timepoints (up to approximately 5 weeks postdose)
- Plasma Total Radioactivity: TmaxTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Total Number of Metabolites in Urine that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)
- Total Number of Metabolites in Feces that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortea CRU Madison (Site 002)
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.